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Abstract
Background: To investigate whether very low mammographic breast density (VLD), HER2, and hormone receptor
status holds any prognostic significance within the different prognostic categories of the widely used Nottingham
Prognostic Index (NPI). We also aimed to see whether these factors could be incorporated into the NPI in an effort
to enhance its performance.
Methods: This study included 270 patients with newly diagnosed invasive breast cancer. Patients with
mammographic breast density of <10 % were considered as VLD. In this study, we compared the performance of
NPI with and without VLD, HER2, ER and PR. Cox multivariate analysis, time-dependent receiver operating
characteristic curve (tdROC), concordance index (c-index) and prediction error (0.632+ bootstrap estimator) were
used to derive an updated version of NPI.
Results: Both mammographic breast density (VLD) (p < 0.001) and HER2 status (p = 0.049) had a clinically significant
effect on the disease free survival of patients in the intermediate and high risk groups of the original NPI
classification. The incorporation of both factors (VLD and HER2 status) into the NPI provided improved patient
outcome stratification by decreasing the percentage of patients in the intermediate prognostic groups, moving a
substantial percentage towards the low and high risk prognostic groups.
Conclusions: Very low density (VLD) and HER2 positivity were prognostically significant factors independent of the
NPI. Furthermore, the incorporation of VLD and HER2 to the NPI served to enhance its accuracy, thus offering a
readily available and more accurate method for the evaluation of patient prognosis.
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Background
Breast cancer is a heterogeneous disease with differing
behaviors and responses to therapy [1, 2]. Therefore,
many prognostic models have been proposed for investi-
gating patient outcome in relation to multiple patient
and disease characteristics and to support clinical deci-
sion making. The Nottingham Prognostic Index (NPI)
was first introduced in 1982 and has since been validated
in independent large multicenter studies with long term
follow up [3–6]. It is based on traditional prognostic
factors such as tumor size, lymph node status and histo-
logical grade. It gives clinicians the ability to predict
both the clinical outcome of tumors and the need for
systemic therapies.
Mammographic breast density (MBD) refers to the
relative abundance of fibrous and glandular tissues
compared to the fat content of the breast as they appear
on a normal X-ray mammogram. Increased MBD is
considered as an established risk factor for breast cancer
development [7], while previous studies reported that in
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patients with already diagnosed breast cancer tumors
originating in breasts with very low density (VLD) were
shown to be associated with a poorer prognosis even
after correcting for possible confounders [8, 9].
Human Epidermal Growth Factor Receptor 2 (HER2)
receptor is a membrane tyrosine kinase and is consid-
ered as a major driver of tumor development and pro-
gression [10]. Patients overexpressing HER2 historically
showed a higher recurrence rates and a generally poorer
outcome [11], but since the introduction of HER2-
directed therapies significant improvements in patients’
outcomes have occurred. Nowadays, several guideline
bodies recommend routine testing of HER2 and also
adjuvant treatment with trastutsumab in HER2-positive
cases [12, 13]. Estrogen receptor (ER) and progesterone
receptor (PR) statuses are also well known prognostic
and predictive factors and play a key role in breast
cancer outcome and treatment [14]. This indicates that
the aforementioned factors that are routinely available
may also have a role in prediction accuracy enhance-
ment if successfully incorporated into scoring systems
such as the NPI.
In this study we set to examine the associations
between very low mammographic breast density (VLD),
HER2 status, ER and PR status in a homogenized patient
group with matched NPI categories. Our main purpose
was to assess whether those variables could be added to
the NPI to form a new more accurate scoring system
with enhanced prognostic and predictive values in order
to better detect patients who are at high risk.
Methods
This study was based on a database of 278 breast carcin-
oma cases which was prospectively gathered to study the
relationship of HER2 status and biological markers. The
criteria for patient selection have been described else-
where [15]. Shortly, 139 consecutive HER2 positive
patients who were operated on in our university hospital
were collected during the years 2002 – 2008 and
matched with an equal amount of HER2 negative breast
cancer cases with matching age and time of operation.
All pathological, clinical and radiological data were
blinded at the time of patient selection with the
exception of HER2 status. The permission for this study
was provided by the ethics committee of University of
Eastern Finland, informed consent for this study was
waived by the Finnish National Supervisor Authority for
Welfare and Health (VALVIRA).
All available digital mammograms of the patients were
then retrospectively collected and the analogue mammo-
grams were digitized and collected into a database.
Many of the patients in the study population have been
diagnosed and referred from other hospitals and centers
from our university hospital’s catchment area which
means that multiple mammographic imaging systems
have been used to obtain the diagnostic images used
in the analyses. The diagnostic mammograms that
first revealed the tumors were chosen for the evalu-
ation as described previously [8]. The percentage of
the area of the mammogram occupied by radiologic-
ally dense breast tissue were assessed using the cra-
niocaudal projections and were determined visually.
Eight patients had to be excluded after the initial
collection because of unsatisfactory mammograms or
missing projections bringing the final number of
patients included in the analysis to 270.
All mammograms were first analyzed independently
and then in consensus by five trained radiologists (three
breast radiology specialists and two residents). The
percentage of the area of the mammogram occupied by
radiologically dense breast tissue was assessed visually
from the craniocaudal projections and then distributed
into six different percentile categories (<5, 5–10, 10–25,
25–50, 50–75 or >75 %). For the purpose of this study,
density was dichotomized into Very Low Density (VLD;
≤10 %) and Mixed Density (MID; >10 %) to allow the
variables to be treated as binary throughout the analysis.
The expression of HER2 gene amplification was deter-
mined by the chromogenic in situ hybridization test
(CISH test) by Zymed SPo-LightTM CISHTM Kit (Zymed
84-0146, San Francisco, CA). Cancers with six or more
gene copies were considered as HER2 positive [16].
The NPI was calculated from the available data using
the formula: NPI = tumor size (in cm) x 0.2 + histological
grade (1–3) + lymph node points (negative node = 1; 1–3
positive node = 2; 4 or more positive node = 3) [17]. NPI
was further subdivided into three prognostic categories: 1)
-low risk, with NPI equal to or less than 3.4; 2) -medium
risk, with NPI between 3.4 and 5.4; 3) -high risk, with NPI
over 5.4.
The baseline characteristics of the patients have been
presented previously [15] and are presented in (Table 1).
The adjuvant treatments were given according to
national guidelines which are in accordance with the
international guidelines [18–20]. Chemotherapy was
provided to 198 patients (73.3 %), hormonal treatment
to 172 (63.7 %), while postoperative radiotherapy was
given to 240 (88.9 %) patients. Adjuvant trastuzumab
was routinely given to all HER2-positive patients from
the year 2005 onwards, while before that it was given to
select patients participating in a trial [21]. HER2-
positive patients received adjuvant trastuzumab in 60
(45.1 %) of the 133 cases. For all events that occurred
to patients in our study population, there was no differ-
ence in treatment plans between patients according to
their dichotomized density profiles (Table 2). Follow up
was collected from medical records and is up to date as of
October 2014.
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Statistical analysis
Statistical analysis was performed with software (SPSS,
version 19; SPSS, Chicago, Ill) and R (version 3.2.0) for
Windows. Patients with bilateral disease (n = 8) had both
breasts analyzed separately, one patient with bilateral
disease and conflicting density readings between the
breasts was integrated in the analysis by choosing the
side with the worse stage and grade. The relationships
between MBD, HER2 and NPI were evaluated using
cross tabulation and McNemar’s non-parametric paired
proportions test. Survival amongst the different patient
groups was compared by the Kaplan-Meier method
using log rank (Mantel-Cox) test. Univariate analysis
was used on different categorical prognostic factors indi-
vidually and Hazard Ratios (HR) with 95 % confidence
intervals were estimated. Cox Multivariate analysis was
then used in a backward stepwise manner to assess the
factors combined until the best fit was obtained and HR
and 95 % CI were recorded. Survival prediction model
for breast cancer patients starting with NPI was followed
by adding more variables to it to improve it and ana-
lyzed by using Cox multivariate analysis, time-dependent
receiver operating characteristic curve (tdROC), con-
cordance index (c-index) and prediction error (i.e. 0.632+
bootstrap estimator).
Results
The average NPI for our patient population was 4.66
(range 2.12–7.40), where 21.5 % (58/270) of patients
belonged to the low risk prognostic group, 47.0 % (127/
270) belonged to the intermediate risk group and 31.5 %
(85/270) to the high risk group. As expected, patients’
disease free survival (DFS) declined with increasing values
of NPI ranging from 91.4 % (53/58), 87.4 % (111/127), to
42.4 % (36/85) for patients in the low, intermediate and
high risk groups of NPI respectively (p < 0.001).
Mammographic breast density, ER and PR statuses
were normally distributed between the different NPI
groups (p = 0.211, p = 0.528, p = 0.472, respectively). The
percentage of HER2 positive patients progressively
increased from the low (29.3 %, 17/58), intermediate
(47.2 %, 60/127) and to the high risk (65.9 %, 56/85)
prognostic groups of NPI (p < 0.001).
As mentioned earlier, patients in the intermediate risk
group of NPI had a DFS of 87.4 % (111/127). The
addition of VLD factor alone (HER2 negative patients)
reduced survival to 82.6 % (19/23). The addition of both
VLD and HER2 positivity at the same time reduced sur-
vival in this intermediate risk category to 70.0 % (14/20).
The patients in this category who were both negative for
HER2 and had MID breasts had a survival of 93.2 % (41/
44), (p = 0.02).
Table 1 Clinicopathological characteristics of the patients





Postmenopausal (%) 66.3 %
Mean tumor size (mm) 22.73
VLD patients 21.47 (6–60)
MID patients 23.46 (3–90)
Mean BMI 26.70
VLD patients 25.46 (20.24–46.87)
MID patients 28.84 (17.96–41.53)
HER2 positive 133 (49.3 %)
Triple Negative 17
Tumor Pathological T classification
T1 152 (56.3 %)
T2 95 (35.2 %)
T3 10 (3.7 %)
T4 13 (4.8 %)
Tumor N classification
N0 100 (37.0 %)
N1 117 (43.3 %)
N2 34 (12.6 %)
N3 19 (7.0 %)
Definitive histology
Ductal 223 (82.6)
Lobular 26 (9.6 %)
Mucinous 4 (1.5 %)
Other 17 (6.3 %)
Histological grade
1 22 (8.1 %)
2 120 (44.4 %)
3 128 (47.4 %)
Follow up time / years
Mean 8.03
Range 0.39–13.22
Table 2 The p values for the differences in treatment options
for patients who died or had a relapse (n = 57) according to






*VLD very low densiy, MID Mixed density
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In the high risk group of NPI, the DFS was 42.4 % (36/
85) as mentioned earlier. The addition of VLD factor
alone (HER2 negative patients) reduced survival to
30.0 % (3/10). The addition of both HER2 positivity and
VLD simultaneously dropped survival to 10.5 % (2/19).
Patients in this high risk category who were both HER2
negative and MID had a relatively better prognosis with
a DFS of 63.2 % (12/19), (p = 0.001).
In our database, ER and PR statuses had no significant
impact on survival in any of the groups of NPI. Unfortu-
nately, the previously described analyses could not be
performed in the low risk group due to the low number
of patients in this group and the low number of events
that have occurred there.
To assess the prognostic powers of those factors in
more detail, we evaluated the survival percentages
according to the different prognostic groups of NPI.
First, as shown in Fig. 1a and b, the DFS for HER2
negative patients was significantly better than for
HER2 positive patients in both the intermediate and
the high risk groups respectively (89.6 vs 85.0 % and
51.7 vs 37.5 %; p = 0.049). The similar observation was
made for patients according to their mammographic
breast density (Fig. 1c and d), as DFS was lower in
patients with VLD breasts both in the intermediate
and high risk NPI groups respectively (92.9 vs 76.7 %,
55.4 vs 17.2 %; p < 0.001).
Five known prognostic factors (ER status, PR status,
HER2 status, breast density and the NPI) first underwent
univariate analysis to assess their prognostic powers on
our patient population. Only three HR values turned out
to be statistically significant (HER2 status, NPI and
VLD). Second, those three factors which retained the
significance were put through Cox multivariate analysis.
The values for both analyses are shown in (Table 3).
Both HER2 and MBD proved to provide prognostic
information independent of NPI.
Incorporating HER2 and MBD into the NPI
NPI, MBD, and HER2 were selected in a final model to
form the Kuopio-Nottingham Prognostic Index (K-NPI)
with parameter estimates of 0.89 (SE, 0.113), 1.01 (SE,
0.246) and 0.51 (SE, 0.258), respectively. Since the par-
ameter estimates of NPI and MBD were highly similar,
the new model was calculated as the sum of those indi-
vidual variables, in addition to + 0.5 for HER2 positivity.
Fig. 1 Patients’ Disease free survival graphs according to HER2 status and their MBDs. Graphis depiciting DFS according to patients’ HER2
receptor status (p = 0.049) separately for patients in the (a) intermediate and (b) high risk NPI groups. Disease free survival graphs according to
patients’ dichotomized mammographic density values. (p < 0.001) separately for patients in the (c) intermediate and (d) high risk NPI groups
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The optimal new cut-offs, obtained with the 0.632+
bootstrap method, were 5.1 and 5.9, the concordance
index of the K-NPI was 0.872 as compared to 0.779 for
the original NPI. As a result, patients in the K-NPI were
now categorized into low-, intermediate-, and high-risk
groups for values below 5.1, between 5.1 and 5.9, and
higher than 5.9, respectively.
The classification of patients into the low, intermediate
and high risk groups according to the K-NPI is com-
pared to the original NPI in (Table 4) and the DFS of
the new groups is illustrated in Fig. 2a and b. The new
system managed to classify considerably less patients
into the intermediate group (55 as compared to 127 in
the original NPI model, p < 0.001) as demonstrated in
(Table 5). Out of the 127 patients previously classified as
intermediate risk, 66 were now classified as low risk, 16
as high risk and 45 remained as intermediate. With
respect to DFS, 92.7 % (115/124), 80.0 % (44/55) and
45.1 % (41/91) were disease free in the low, intermediate
and high risk groups according to the KNPI respectively
at the end of the follow up period.
Discussion
Breast cancer is a heterogeneous disease with varying
phenotypes, genotypes, behaviours and responses to
therapy. Adjuvant systemic treatments have helped to
significantly decrease patient mortality. However, it is
still difficult to evaluate which patients will benefit from
adjuvant treatments and which patients will end up
suffering from their toxicity [22, 23]. The principle find-
ing of this study was that both HER2 status and very low
mammographic breast density (VLD) proved to be inde-
pendent of the classically used NPI and serve to improve
its predictive ability. In our patient population, the ori-
ginal NPI classified a rather high proportion of patients
into the intermediate risk group making it challenging to
evaluate the need and benefit of adjuvant chemotherapy.
With the new K-NPI, a considerable group of patients
were moved from the intermediate to the low or high
risk groups which might hold clinical significance in
terms of adjuvant treatment decisions.
In line with our results, several studies have shown
that HER2 status is a predictive factor independent of
the NPI [24–26]. Although Van Belle et al. [26] managed
to create a new prognostic classification system (dubbed
the iNPI) by incorporating both HER2 and Progesterone
status into the NPI, our results in contrast indicated that
neither ER nor PR statuses were prognostically signifi-
cant, which is in line with studies proposing that
hormone receptors lose their prognostic power in the
long term [27].
Previous studies have investigated the addition of several
different factors to the NPI and whether those could serve
to improve its predictive value in regards to patient
prognosis [26, 28–31]. Mammographic breast density how-
ever has never been incorporated into a prognostic index
before this trial, even though it is a routinely available,
cost-free and easily interpreted parameter in patients with
newly diagnosed breast cancer. Our results now show that
MBD is a predictive factor independent of the NPI.
Furthermore, it can be added to NPI simultaneously with
HER2 status to give a synergistic advantage to its predictive
ability, especially in the ubiquitous intermediate prognostic
category of NPI. It can be clearly seen that MBD and
HER2 status were major determinants in switching
patients from the original NPI intermediate group to the
new K-NPI low risk and high risk groups, density as shown
in Table 6.
Our study is not without limitations. Our patient
population is relatively small and we only had a limited
Table 3 Hazard ratios of the prognostic factors in both the
univariate and cox multivariate analysis
Prognostic factor HR P 95 % CI
Univariate analysis
HER2 status 2.325 0.001 1.415–3.820
MBD (VLD) 1.986 0.004 1.238–3.187
NPI 2.295 <0.001 1.845–2.854
ER Status 0.995 0.986 0.596–1.662
PR Status 1.135 0.613 0.695–1.851
Multivariate analysis
HER2 status 1.673 0.046 1.010–2.772
NPI 2.338 <0.001 1.872–2.920
MBD (VLD) 2.790 <0.001 1.724–4.516
Table 4 Comparison between DFS in risk groups of the newly formed KNPI and the original NPI
New Classification KNPI Original NPI p
Group Patients (%) DFS Patients (%) DFS
Low risk 124 (45.9) 92.7 % (115/124) 58 (21.5) 91.4 % (53/58) <0.001
Intermediate risk 55 (20.4) 80.0 % (44/55) 127 (47.0) 87.4 % (111/127)
High risk 91 (33.7) 45.1 % (41/91) 85 (31.5) 42.4 % (36/85)
C Index 0.872 0.779
The distribution of patients into the newly formed low, intermediate and high risk groups of the Kuopio-Nottingham Prognostic Index with their respective
Disease Free Survival, compared to the old categories of the original Nottingham Prognostic Index
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number of triple negative cancers. And due to our
patient selection criteria, our study had a higher percent-
age of HER2 positive patients than fully consecutive
cohorts. Many of our patients have been treated with
adjuvant therapies making it difficult to predict the exact
role of the primary prognostic factors and how the treat-
ments have affected the results. However, at the time of
patient collection, the national guidelines in Finland were
very similar to current guidelines. A notable exception
was the addition of trastuzumab as a standard to HER2
positive patients in the year 2005, while before that trastu-
zumab was offered only for patients participating in the
FinHer trial [21]. Furthermore, mammographic density
was measured visually which may be considered less
accurate by some, but we aimed to select a method that is
easily reproducible in clinical practice and does not
require the addition of expensive and sometimes compli-
cated programs.
Fig. 2 Graphs depicting DFS curves for risk groups of (a) the original NPI and (b) the newly coined KNPI
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Another commonly used tool to evaluate patient
outcome nowadays is the Adjuvant! Online prognostic
index. It is an internet based computer programme
providing 10-year prognosis predictions for early breast
cancer patients. Its use has increased in recent years;
however, its validation in different cohorts has not been
as successful as its counterpart the NPI with many
studies finding wide discrepancies between its reported
predictions and actual survivals [32–34].
In the future, prognostic classification may benefit
from newer methods such as microarray-based gene ex-
pression profiling [35]. Multigene signatures associated
with prognosis have recently emerged and some are even
commercially available [36]. Drukker et al. [37] showed a
prognostic benefit by combining the 70-gene signature
with the classical scoring systems. Nevertheless, these
gene signatures carry many shortcomings, different
multigene tests give different and variating results mak-
ing their implementation into clinical practice difficult
[38, 39]. This may be due to intratumoral genetic
variation and heterogeneity in the microenvironment.
Although these new markers may provide additional
prognostic data, only a very limited number of patients
could benefit from them due to the high costs of the
tests. Thus, if we consider breast cancer as a global
prolem, the classical clinical markers are still needed and
new multigene tests should be considered complimentary
and not a replacement for traditional parameters [40, 41].
Many breast cancer cases are diagnosed in the developing
world where resources are scarce making those disadvan-
tages particularly important, and that’s where the need
stems for new, simple and easily available prognostic
factors that are easy to interpret and can be easily
combined with the classical clinicopathological scoring
systems [23, 42]. HER2 status is nowadays measured rou-
tinely in most countries, and MBD can be easily acquired
from the diagnostic mammograms, hence not requiring
any extra time or money.
Conclusions
In conclusion, our results show that for patients with
early breast cancer MBD and HER2 status are indeed
strong prognostic factors independent of the NPI.
Furthermore, we were able to enhance the prognostic
ability of NPI by the addition of HER2 status and breast
density values into the newly coined K-NPI. This prog-
nostic reclassification managed to significantly decrease
the percentage of patients in the intermediate risk group,
which serves to more reliably recognize those patients
who are in the real higher risk group. Future work with
larger patient populations, and with quantitative density
measurement methods must be carried out to validate
the clinical utility of our observations.
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